Suppr超能文献

日本血脂异常和心血管疾病高危患者采用初始他汀类单药治疗的低密度脂蛋白胆固醇目标达标率:一项回顾性数据库分析。

Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan - A Retrospective Database Analysis.

机构信息

Department of Medical Affairs, MSD K.K.

Center for Observational and Real-world Evidence, MSD Ltd.

出版信息

Circ J. 2018 May 25;82(6):1605-1613. doi: 10.1253/circj.CJ-17-0971. Epub 2018 Apr 7.

Abstract

BACKGROUND

To understand the recent management status in Japan, we determined the low-density lipoprotein cholesterol (LDL-C) goal attainment (GA) rate of patients initiating statin monotherapy for dyslipidemia.

METHODS AND RESULTS

Dyslipidemic patients undergoing either primary prevention with high cardiovascular risk or secondary prevention (defined by 2012 Japan Atherosclerosis Society Guidelines) were retrospectively analyzed from a hospital-based claims database. In both groups, the LDL-C levels and GA rates of patients treated with intensive or standard statin monotherapy for ≥4 weeks (January 2012-August 2016) were evaluated. Among 1,501,013 dyslipidemic patients, 11,695 and 9,642 were included in the primary and secondary prevention groups, respectively. A total of 94% of patients underwent statin monotherapy as the initial lipid-lowering therapy, of which most (≥80%) took intensive statins. The proportions of patients in the primary prevention group who achieved an LDL-C goal <120 mg/dL by intensive and standard statins were 81.1% and 61.2%, respectively, and the proportions of those who achieved a goal <100 mg/dL in the secondary prevention group were 73.3% and 48.1%, respectively. The GA rates were similar regardless of disease complications.

CONCLUSIONS

Most patients (>70%) in both groups achieved LDL-C management goals using intensive statin monotherapy. Further treatment approaches are required for high-risk patients not achieving LDL-C goals by initial statin monotherapy. Continuous efforts are crucial for adherence and persistence of lipid-lowering therapies.

摘要

背景

为了了解日本的最新管理现状,我们确定了因血脂异常开始他汀类药物单药治疗的患者的低密度脂蛋白胆固醇(LDL-C)目标达标率(GA)。

方法和结果

从医院的索赔数据库中回顾性分析了接受高心血管风险一级预防或二级预防(根据 2012 年日本动脉粥样硬化学会指南定义)的血脂异常患者。在这两组患者中,评估了接受强化或标准他汀类药物单药治疗≥4 周(2012 年 1 月至 2016 年 8 月)的患者的 LDL-C 水平和 GA 率。在 1501013 名血脂异常患者中,分别有 11695 名和 9642 名患者被纳入一级和二级预防组。94%的患者接受他汀类药物单药治疗作为初始降脂治疗,其中大多数(≥80%)服用强化他汀类药物。在一级预防组中,接受强化和标准他汀类药物治疗后 LDL-C 目标<120mg/dL 的患者比例分别为 81.1%和 61.2%,而在二级预防组中,这一比例分别为 73.3%和 48.1%。无论疾病并发症如何,GA 率都相似。

结论

两组患者中超过 70%的患者通过强化他汀类药物单药治疗达到 LDL-C 管理目标。对于初始他汀类药物单药治疗未能达到 LDL-C 目标的高危患者,需要进一步的治疗方法。对于降脂治疗的依从性和持久性,持续的努力至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验